The Taiwan Conventional PCR market has experienced notable growth, driven by a robust healthcare sector and advancements in the biomedical industry. Supported by initiatives such as the Biomedical Industry Innovation Program (BIIP) under the 5+2 Innovative Industries Plan, the biomedical sector achieved $9.9 billion in revenue in 2023, marking 5% YoY growth.
Backed by the Development of Biotechnology Act, demand for PCR technology has surged in genetic testing, diagnostics, and pharmaceutical research. Additionally, Taiwan’s efficient National Health Insurance (NHI), covering 99.9% of the population, along with $9.1 million investment in telemedicine in 2023, has further reinforced the country’s healthcare system.
According to the research, Taiwan Conventional PCR Market is projected to grow at a CAGR of 2.9% from 2024-2030F. The ongoing market expansion is projected to continue, driven by the rising prevalence of infectious diseases, with notifiable communicable disease cases reaching 84,815 in 2023 and expected to rise further. This growth is also fueled by Taiwan’s aging population, set to transition into a “super-aged society” by 2025, which underscores the increasing demand for diagnostic tools to enable timely disease detection and continuous monitoring. The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) has also played a vital role, by attracting over $1.5 billion in annual investments.
Key strategic collaborations, such as the 2023 Taiwan-US Cancer Moonshot Project and ASUS-Roche partnerships, alongside Taiwan's goal of developing a trillion-NT-dollar biomedical industry by 2025, are significantly contributing to the market expansion. Furthermore, government initiatives, including the Healthy Taiwan Initiative, Health for All Ages 2030, and the National Development Council’s focusing on precision healthcare, are driving demand for PCR testing through programs like TPHI and TPMI. These factors are set to accelerate the adoption of PCR technology, making it indispensable for precision medicine and diagnostics, and fuelled the Conventional PCR market growth in Taiwan.
Backed by the Development of Biotechnology Act, demand for PCR technology has surged in genetic testing, diagnostics, and pharmaceutical research. Additionally, Taiwan’s efficient National Health Insurance (NHI), covering 99.9% of the population, along with $9.1 million investment in telemedicine in 2023, has further reinforced the country’s healthcare system.
According to the research, Taiwan Conventional PCR Market is projected to grow at a CAGR of 2.9% from 2024-2030F. The ongoing market expansion is projected to continue, driven by the rising prevalence of infectious diseases, with notifiable communicable disease cases reaching 84,815 in 2023 and expected to rise further. This growth is also fueled by Taiwan’s aging population, set to transition into a “super-aged society” by 2025, which underscores the increasing demand for diagnostic tools to enable timely disease detection and continuous monitoring. The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) has also played a vital role, by attracting over $1.5 billion in annual investments.
Key strategic collaborations, such as the 2023 Taiwan-US Cancer Moonshot Project and ASUS-Roche partnerships, alongside Taiwan's goal of developing a trillion-NT-dollar biomedical industry by 2025, are significantly contributing to the market expansion. Furthermore, government initiatives, including the Healthy Taiwan Initiative, Health for All Ages 2030, and the National Development Council’s focusing on precision healthcare, are driving demand for PCR testing through programs like TPHI and TPMI. These factors are set to accelerate the adoption of PCR technology, making it indispensable for precision medicine and diagnostics, and fuelled the Conventional PCR market growth in Taiwan.
Market Segmentation By Product
Software & Services in the Taiwan PCR market is expected to experience the highest growth in coming years due to increasing demand for advanced data analysis, real-time monitoring, and workflow integration in PCR applications. With rising complexity in PCR processes, the need for specialized software for data management, assay design, and cloud-based solutions would drive innovation, leading to significant growth in this segment.Key Attractiveness of the Report
- 10 Years Market Numbers.
- Historical Data Starting from 2020 to 2023.
- Base Year: 2023
- Forecast Data until 2030.
- Key Performance Indicators Impacting the Market.
- Major Upcoming Developments and Projects.
Key Highlights of the Report:
- Taiwan Conventional PCR Market Overview
- Taiwan Conventional PCR Market Outlook
- Taiwan Conventional PCR Market Forecast
- Industry Life Cycle
- Porter’s Five Forces Analysis
- Historical Data and Forecast of Taiwan Conventional PCR Market Revenues for the Period 2020-2030F
- Historical Data and Forecast of Taiwan Conventional PCR Market Revenues, By Product, for the Period 2020-2030F
- Market Drivers and Restraints
- Market Trends
- Market Opportunity Assessment
- Competitive Benchmarking
- Company Profiles
- Key Strategic Recommendations
Market Scope and Segmentation
The report provides a detailed analysis of the following market segments:
By Product- Consumables & Reagents
- Instruments
- Software & Services
Table of Contents
1. Executive Summary5. Taiwan Conventional PCR Market Trends & Evolution7. Taiwan Conventional PCR Market Key Performance Indicators10. Company Profiles11. Key Strategic Recommendations12. Disclaimer
2. Introduction
3. Taiwan Conventional PCR Market Overview
4. Taiwan Conventional PCR Market Dynamics
6. Taiwan Conventional PCR Market Overview, By Product
8. Taiwan Conventional PCR Market Opportunity Assessment
9. Taiwan Conventional PCR Market Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- F. Hoffmann-La Roche
- Qiagen
- Abbott Laboratories
- Becton, Dickinson and Company (BD)
